Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for CINV in Breast Cancer
NCT00092183Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2002
- Primary completion
- Dec 2003
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Merck & Co. Primary endpoints: Emesis and use of rescue medication and Safety and tolerability. Started Oct 2002; status: completed.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT00092183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092183.